A humanized anti-CD52 monoclonal antibody, Alemtuzumab, has been approved for the treatment of relapsing multiple sclerosis (Li et al., 2018; Zhao et al., 2017), suggesting its potential benefit in nephritis. The gene discussed is CD52; the disease is nephritis.